News

(RTTNews) - Entrada Therapeutics (TRDA) reported positive preliminary data from Phase 1 clinical trial with ENTR-601-44 for Duchenne Muscular Dystrophy, ENTR-601-44-101. The company said ENTR-601-44 was well tolerated in healthy volunteers and showed significant plasma concentration, muscle concentration and exon skipping.

"We achieved the goals of the ENTR-601-44-101 trial, including the identification of a clinically relevant starting dose for the planned Phase 2 global patient study," said Dipal Doshi, CEO.

The company said it is on track to submit regulatory applications in the fourth quarter of 2024 to initiate separate global Phase 2 clinical trials for ENTR-601-44 in patients with Duchenne who are exon 44 skipping amenable and for ENTR-601-45 in patients with Duchenne who are exon 45 skipping amenable.

For More Such Health News, visit rttnews.com.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.